XML 25 R17.htm IDEA: XBRL DOCUMENT
v3.22.1

Equity-Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2022
Share-based Payment Arrangement, Noncash Expense [Abstract] |
Equity-Based Compensation | NO TE 8. EQUITY-BASED COMPENSATION At March 31, 2022, approximately 0.7 million shares are available for future use under our long-term incentive plans. Share-based compensation activity during the three months ended March 31, 2022 included the following:
(Shares in thousands) |  | Granted |  |  | Vested |  |  | Forfeited |
Performance Share Awards (PSAs) |  |  | 92,490 |  |  |  | — |  |  |  | 971 |
Restricted Stock Units (RSUs) |  |  | 34,324 |  |  |  | 500 |  |  |  | 1,323 |
Approximately 0.3 million shares of common stock were issued to employees during the three months ended March 31, 2022 as a result of PSA and RSU vesting during 2021 and 2022. The following table details equity-based compensation expense and the related income tax benefit:
|  | Three Months Ended March 31, |
(in thousands) |  | 2022 |  |  | 2021 |
Equity-based compensation expense: |  |  |  |  |  |
Performance share awards |  | $ | 1,298 |  |  | $ | 1,224 |
Restricted stock units |  |  | 709 |  |  |  | 665 |
Deferred compensation stock equivalent units expense |  |  | 49 |  |  |  | 41 |
Total equity-based compensation expense |  | $ | 2,056 |  |  | $ | 1,930 |
Total tax benefit recognized for equity-based expense |  | $ | 100 |  |  | $ | 89 |
Performance Share Awards The weighted average grant date fair value of PSAs granted in 2022 was $76.18 per share. PSAs granted under the stock incentive plans have a three-year performance period and shares are issued at the end of the period if the performance measures are met. The number of shares actually issued, as a percentage of the amount subject to the PSA, could range from 0% to 200%. PSAs granted under the stock incentive plans do not have voting rights unless and until shares are issued upon settlement. If shares are issued at the end of the performance measurement period, the recipients will receive dividend equivalents in the form of additional shares at the time of payment equal to the dividends that would have been paid on the shares earned had the recipients owned the shares during the three-year period. Therefore, the shares are not considered participating securities. The following table presents the key inputs used in the Monte Carlo simulation to calculate the fair value of the performance share awards granted in 2022:
Stock price as of valuation date |  | $ | 55.02 |
Risk-free rate |  |  | 1.79 | %
Expected volatility |  |  | 45.69 | %
Expected dividend yield 1 |  |  | — |
Expected term (years) |  |  | 3.00 |
1 | Full dividend reinvestment assumed.
Restricted Stock Units The weighted average fair value of all RSUs granted during the three months ended March 31, 2022 was $54.79 per share. The fair value of RSUs granted equaled our common share price on the date of grant factoring in any required post-vesting holding periods. The RSU awards granted accrue dividend equivalents based on dividends paid during the RSU vesting period. Recipients will receive dividend equivalents in the form of additional shares of common stock at the date the vested RSUs are settled. Any forfeited RSUs will not receive dividends. Therefore, the shares are not considered participating securities.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration